<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986010</url>
  </required_header>
  <id_info>
    <org_study_id>V160-001</org_study_id>
    <nct_id>NCT01986010</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)</brief_title>
  <official_title>A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and immunogenicity of various doses,&#xD;
      formulations, and routes of administration of Human Cytomegalovirus (HCMV) vaccine V160&#xD;
      administered in a 3-dose regimen in healthy adults. The initial treatment arm of HCMV&#xD;
      seropositive participants will receive V160 Low Dose without adjuvant by intramuscular&#xD;
      injection. Escalation of the V160 dose, inclusion of adjuvant, administration by intradermal&#xD;
      injection, and vaccination of HCMV seronegative participants will be performed only after&#xD;
      review of safety data of previous treatment arms. The purpose of the study is to identify&#xD;
      vaccine formulations associated with optimal safety profile and HCMV-specific immune response&#xD;
      for evaluation in subsequent clinical studies of V160.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 25, 2013</start_date>
  <completion_date type="Actual">March 14, 2017</completion_date>
  <primary_completion_date type="Actual">April 19, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With an Adverse Event (AE)</measure>
    <time_frame>Up to 2 weeks after vaccination on Day 1, Month 1 and Month 6 (up to Day 15, Week 6 and Week 26)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With an Injection-site AE</measure>
    <time_frame>Up to 2 weeks after vaccination on Day 1, Month 1 and Month 6 (up to Day 15, Week 6 and Week 26)</time_frame>
    <description>Injection-site AEs are defined as redness, swelling, and pain/tenderness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Systemic AE</measure>
    <time_frame>Up to 2 weeks after vaccination on Day 1, Month 1 and Month 6 (up to Day 15, Week 6 and Week 26)</time_frame>
    <description>A Systemic AE includes, but is not exclusive of, the following AEs: fatigue, myalgia, headache and joint pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Serious Adverse Event (SAE)</measure>
    <time_frame>Up to 2 weeks after vaccination on Day 1, Month 1 and Month 6 (up to Day 15, Week 6 and Week 26)</time_frame>
    <description>A serious adverse event is any adverse event occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Serious Vaccine-Related Adverse Event</measure>
    <time_frame>Up to 2 weeks after vaccination on Day 1, Month 1 and Month 6 (up to Day 15, Week 6 and Week 26)</time_frame>
    <description>A serious adverse event is any adverse event occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. A serious vaccine-related adverse event was determined by the investigator to be related to the vaccine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Treatment Due to an AE</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Events of Clinical Interest (ECI)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>An event of clinical interest (ECI) is identified as any overdose, elevated liver values meeting threshold criteria (aspartate aminotransferase or alanine aminotransferase ≥3x upper limit of normal (ULN); total bilirubin ≥2x ULN, and, at the same time, alkaline phosphatase &lt;2xULN). Additionally, confirmed, diagnosed autoimmune conditions are considered ECIs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer of HCMV-specific Neutralizing Antibody After Vaccination 3</measure>
    <time_frame>Month 7 (1 month after vaccination 3 at Month 6)</time_frame>
    <description>Serum samples for measuring neutralizing antibodies using the Merck Neutralizing Antibody (NAb) assay were collected at month 7. The LiCor-based near-infrared dye (NIRDye) In-Cell Western (ICW) HCMV microneutralization assay was used to detect and quantify anti-HCMV neutralizing antibodies. The primary hypothesis was that for HCMV-seronegative participants, at least 1 of the vaccination groups receiving V160 formulated with or without adjuvant would exhibit higher HCMV-specific neutralizing antibody titers than the placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Count of Peripheral Blood Mononuclear Cells Secreting Interferon-Gamma</measure>
    <time_frame>Month 7 (1 month after vaccination 3 at Month 6)</time_frame>
    <description>In order to evaluate the cellular immune response to the vaccine(s), the HCMV enzyme-linked immunospot (ELISPOT) assay was used to detect interferon gamma (IFN-γ) secreting HCMV-specific cells from peripheral blood mononuclear cells (PBMCs). Results are expressed as the frequency of spot forming cells (SFCs) per million PBMCs (SFC/10^6 PBMCs). Results are presented for the following HCMV proteins: pp65, Immediate early Protein 1 (IE1), Immediate early Protein 2 (IE2), Glycoprotein B (gB), and also for purified HCMV virion stock.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Interferon-Gamma After Stimulation of Whole Blood Sample With Pooled HCMV Antigen Peptides</measure>
    <time_frame>Month 7 (1 month after vaccination 3 at Month 6)</time_frame>
    <description>In response to HCMV-specific stimulation of whole blood specimens the whole Blood Cytokine Stimulation (WBStim) assay was used to detect the secretion of interferon gamma (IFN -γ) by an ELISA assay. Results are presented for the following HCMV proteins: pp65, IE1, and gB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of HCMV-specific Neutralizing Antibody After Vaccinations 1 and 2</measure>
    <time_frame>Month 1 and 2 (one month after vaccination 1 [Day 1] and vaccination 2 [Month 1])</time_frame>
    <description>Serum samples for measuring neutralizing antibodies using the Merck NAb assay were collected at months 1 and 2. The LiCor-based near-infrared dye (NIRDye) In-Cell Western (ICW) HCMV microneutralization assay was used to detect and quantify anti-HCMV neutralizing antibodies. Values below the lower limit of titer are represented by NA.</description>
  </secondary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>HCMV seropositive (+) V160 Low Dose Intramuscular (IM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV seronegative (-) V160 Low Dose IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV+ V160 Medium Dose IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- V160 Medium Dose IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV+ V160 High Dose IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- V160 Medium Dose plus MAPA 225 µg IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- V160 High Dose IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV+ V160 High Dose plus MAPA 225 µg IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV+ V160 Maximum Dose IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- V160 High Dose plus MAPA 225 µg IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- V160 Maximum Dose IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV+ Placebo IM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- Placebo IM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV+ V160 Medium Dose Intradermal (ID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- V160 Medium Dose ID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV+ Placebo ID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants seropositive for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCMV- Placebo ID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants seronegative for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160 Low Dose IM</intervention_name>
    <description>V160 administered as a 0.75 mL intramuscular injection</description>
    <arm_group_label>HCMV seronegative (-) V160 Low Dose IM</arm_group_label>
    <arm_group_label>HCMV seropositive (+) V160 Low Dose Intramuscular (IM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160 Medium Dose IM</intervention_name>
    <description>V160 administered as a 0.75 mL intramuscular injection</description>
    <arm_group_label>HCMV+ V160 Medium Dose IM</arm_group_label>
    <arm_group_label>HCMV- V160 Medium Dose IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160 High Dose IM</intervention_name>
    <description>V160 administered as a 0.75 mL intramuscular injection</description>
    <arm_group_label>HCMV+ V160 High Dose IM</arm_group_label>
    <arm_group_label>HCMV- V160 High Dose IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM</intervention_name>
    <description>V160 plus MAPA administered as a 0.75 mL intramuscular injection</description>
    <arm_group_label>HCMV- V160 Medium Dose plus MAPA 225 µg IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160 High Dose plus MAPA 225 µg /dose IM</intervention_name>
    <description>V160 plus MAPA administered as a 0.75 mL intramuscular injection</description>
    <arm_group_label>HCMV+ V160 High Dose plus MAPA 225 µg IM</arm_group_label>
    <arm_group_label>HCMV- V160 High Dose plus MAPA 225 µg IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160 Maximum Dose IM</intervention_name>
    <description>V160 administered as a 0.75 mL intramuscular injection</description>
    <arm_group_label>HCMV+ V160 Maximum Dose IM</arm_group_label>
    <arm_group_label>HCMV- V160 Maximum Dose IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo IM</intervention_name>
    <description>Placebo administered as a 0.75 mL intramuscular injection</description>
    <arm_group_label>HCMV+ Placebo IM</arm_group_label>
    <arm_group_label>HCMV- Placebo IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160 Medium Dose ID</intervention_name>
    <description>V160 administered as a 0.1 mL intradermal injection</description>
    <arm_group_label>HCMV+ V160 Medium Dose Intradermal (ID)</arm_group_label>
    <arm_group_label>HCMV- V160 Medium Dose ID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo ID</intervention_name>
    <description>Placebo administered as a 0.1 mL intradermal injection</description>
    <arm_group_label>HCMV+ Placebo ID</arm_group_label>
    <arm_group_label>HCMV- Placebo ID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy based on medical history and physical examination&#xD;
&#xD;
          -  Serologically confirmed to be HCMV seronegative or HCMV seropositive&#xD;
&#xD;
          -  Agrees to avoid unusual, unaccustomed strenuous, vigorous physical exercise/activity&#xD;
             from 72 hours before through 72 hours after each dose of study vaccine&#xD;
&#xD;
          -  Body weight ≥110 lbs (50 kg) and body mass index (BMI) of 19 to 32 kg/m^2&#xD;
&#xD;
          -  If of reproductive potential, agrees to the following during the study and for 4 weeks&#xD;
             after the last dose of study vaccine: 1) practice abstinence from heterosexual&#xD;
             activity, or 2) use or have their partner use 2 allowable methods of birth control&#xD;
             during heterosexual activity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has previously received any cytomegalovirus vaccine&#xD;
&#xD;
          -  Has history of allergic reaction or anaphylactic reaction to any vaccine component&#xD;
             that required medical intervention&#xD;
&#xD;
          -  Has history of any severe allergic reaction that required medical intervention&#xD;
&#xD;
          -  Is pregnant or breastfeeding or expecting to conceive from 2 weeks before the study&#xD;
             through 1 month after the last dose of study vaccine&#xD;
&#xD;
          -  Plans to donate eggs or sperm from study start through 1 month after the last dose of&#xD;
             study drug&#xD;
&#xD;
          -  Has impairment of immunologic function including, but not limited to autoimmune&#xD;
             disease, splenectomy, or human immunodeficiency virus acquired immunodeficiency&#xD;
             syndrome (HIV/AIDS)&#xD;
&#xD;
          -  Received systemic corticosteroids for ≥14 consecutive days and has not completed&#xD;
             treatment within 30 days of study start&#xD;
&#xD;
          -  Received immunosuppressive therapy including, but not limited to rapamycin and&#xD;
             equivalents, tacrolimus, FK-506, fujimycin, or other therapies used for solid&#xD;
             organ/cell transplant, radiation therapy, immunosuppressive/cytotoxic chemotherapy, or&#xD;
             other therapy known to interfere with the immune response within 1 year of study start&#xD;
&#xD;
          -  Has a condition in which repeated venipuncture or injections pose more than minimal&#xD;
             risk, such as hemophilia, thrombocytopenia or other severe coagulation disorders, or&#xD;
             significantly impaired venous access&#xD;
&#xD;
          -  Has a condition that requires active medical intervention or monitoring such as&#xD;
             diabetes mellitus, autoimmune disease, or a clinically significant chronic medical&#xD;
             condition that is considered progressive&#xD;
&#xD;
          -  Has history within the past 5 years or current drug or alcohol abuse&#xD;
&#xD;
          -  Has major psychiatric illness&#xD;
&#xD;
          -  Is legally or mentally incapacitated&#xD;
&#xD;
          -  Has participated in another clinical study in the past 4 weeks, or plans during the&#xD;
             present study to participate in a treatment-based study or a study in which an&#xD;
             invasive procedure is performed&#xD;
&#xD;
          -  Has received valganciclovir, ganciclovir, valacyclovir, foscarnet, or cidofovir from 4&#xD;
             weeks prior to 1 month following each V160 vaccination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 11, 2013</study_first_submitted>
  <study_first_submitted_qc>November 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <results_first_submitted>September 30, 2021</results_first_submitted>
  <results_first_submitted_qc>September 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2021</results_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy males and females age 18 years of age and older were enrolled in this trial.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>HCMV Seropositive (+) V160 10u Intramuscular (IM)</title>
          <description>Participants seropositive for Human cytomegalovirus (HCMV) at Baseline received 10 units (u) V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P2">
          <title>HCMV + V160 30u IM</title>
          <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P3">
          <title>HCMV+ V160 100u IM</title>
          <description>Participants seropositive for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P4">
          <title>HCMV+ V160 100u MAPA IM</title>
          <description>Participants seropositive for HCMV at Baseline received 100u V160 plus Merck Aluminum Phosphate Adjuvant (MAPA) adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P5">
          <title>HCMV+ V160 250u IM</title>
          <description>Participants seropositive for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P6">
          <title>HCMV+ Placebo IM</title>
          <description>Participants seropositive for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P7">
          <title>HCMV+ V160 30u ID</title>
          <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by intradermal (ID) injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P8">
          <title>HCMV+ Placebo ID</title>
          <description>Participants seropositive for HCMV at Baseline received vaccination with placebo by ID injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P9">
          <title>HCMV Seronegative (-) V160 10u IM</title>
          <description>Participants seronegative for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P10">
          <title>HCMV- V160 30u IM</title>
          <description>Participants seronegative for HCMV at Baseline received vaccination with 30u V160 by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P11">
          <title>HCMV- V160 30u MAPA IM</title>
          <description>Participants seronegative for HCMV at Baseline received 30u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P12">
          <title>HCMV- V160 100u IM</title>
          <description>Participants seronegative for HCMV at Baseline received 100u V160 by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P13">
          <title>HCMV- V160 100u MAPA IM</title>
          <description>Participants seronegative for HCMV at Baseline received 100u V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P14">
          <title>HCMV- V160 250u IM</title>
          <description>Participants seronegative for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P15">
          <title>HCMV- V160 Placebo IM</title>
          <description>Participants seronegative for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P16">
          <title>HCMV- V160 30u ID</title>
          <description>Participants seronegative for HCMV at Baseline received 30u V160 by ID injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="P17">
          <title>HCMV- Placebo ID</title>
          <description>Participants seronegative for HCMV at Baseline received placebo by ID injection on Day 1, Month 1, and Month 6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="10"/>
                <participants group_id="P12" count="11"/>
                <participants group_id="P13" count="10"/>
                <participants group_id="P14" count="11"/>
                <participants group_id="P15" count="16"/>
                <participants group_id="P16" count="11"/>
                <participants group_id="P17" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 1</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="10"/>
                <participants group_id="P12" count="11"/>
                <participants group_id="P13" count="10"/>
                <participants group_id="P14" count="11"/>
                <participants group_id="P15" count="16"/>
                <participants group_id="P16" count="11"/>
                <participants group_id="P17" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 2</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="11"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="10"/>
                <participants group_id="P12" count="10"/>
                <participants group_id="P13" count="10"/>
                <participants group_id="P14" count="9"/>
                <participants group_id="P15" count="16"/>
                <participants group_id="P16" count="10"/>
                <participants group_id="P17" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 3</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="10"/>
                <participants group_id="P12" count="8"/>
                <participants group_id="P13" count="10"/>
                <participants group_id="P14" count="9"/>
                <participants group_id="P15" count="13"/>
                <participants group_id="P16" count="10"/>
                <participants group_id="P17" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="6"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="10"/>
                <participants group_id="P13" count="10"/>
                <participants group_id="P14" count="11"/>
                <participants group_id="P15" count="10"/>
                <participants group_id="P16" count="11"/>
                <participants group_id="P17" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Status Not Recorded</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="9"/>
                <participants group_id="P14" count="9"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="10"/>
                <participants group_id="P17" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HCMV Seropositive (+) V160 10u Intramuscular (IM)</title>
          <description>Participants seropositive for Human cytomegalovirus (HCMV) at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B2">
          <title>HCMV + V160 30u IM</title>
          <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B3">
          <title>HCMV+ V160 100u IM</title>
          <description>Participants seropositive for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B4">
          <title>HCMV+ V160 100u MAPA IM</title>
          <description>Participants seropositive for HCMV at Baseline received 100u V160 plus Merck Aluminum Phosphate Adjuvant (MAPA) adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B5">
          <title>HCMV+ V160 250u IM</title>
          <description>Participants seropositive for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B6">
          <title>HCMV+ Placebo IM</title>
          <description>Participants seropositive for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B7">
          <title>HCMV+ V160 30u ID</title>
          <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by intradermal (ID) injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B8">
          <title>HCMV+ Placebo ID</title>
          <description>Participants seropositive for HCMV at Baseline received vaccination with placebo by ID injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B9">
          <title>HCMV Seronegative (-) V160 10u IM</title>
          <description>Participants seronegative for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B10">
          <title>HCMV- V160 30u IM</title>
          <description>Participants seronegative for HCMV at Baseline received vaccination with 30u V160 by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B11">
          <title>HCMV- V160 30u MAPA IM</title>
          <description>Participants seronegative for HCMV at Baseline received 30u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B12">
          <title>HCMV- V160 100u IM</title>
          <description>Participants seronegative for HCMV at Baseline received 100u V160 by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B13">
          <title>HCMV- V160 100u MAPA IM</title>
          <description>Participants seronegative for HCMV at Baseline received 100u V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B14">
          <title>HCMV- V160 250u IM</title>
          <description>Participants seronegative for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B15">
          <title>HCMV- V160 Placebo IM</title>
          <description>Participants seronegative for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B16">
          <title>HCMV- V160 30u ID</title>
          <description>Participants seronegative for HCMV at Baseline received 30u V160 by ID injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B17">
          <title>HCMV- Placebo ID</title>
          <description>Participants seronegative for HCMV at Baseline received placebo by ID injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="B18">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="11"/>
            <count group_id="B6" value="19"/>
            <count group_id="B7" value="10"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="12"/>
            <count group_id="B10" value="10"/>
            <count group_id="B11" value="10"/>
            <count group_id="B12" value="11"/>
            <count group_id="B13" value="10"/>
            <count group_id="B14" value="11"/>
            <count group_id="B15" value="16"/>
            <count group_id="B16" value="11"/>
            <count group_id="B17" value="4"/>
            <count group_id="B18" value="190"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.1" spread="14.8"/>
                    <measurement group_id="B2" value="47.7" spread="14.5"/>
                    <measurement group_id="B3" value="44.9" spread="13.2"/>
                    <measurement group_id="B4" value="48.8" spread="10.6"/>
                    <measurement group_id="B5" value="46.4" spread="13.7"/>
                    <measurement group_id="B6" value="46.5" spread="15.1"/>
                    <measurement group_id="B7" value="51.7" spread="18.9"/>
                    <measurement group_id="B8" value="47.5" spread="16.7"/>
                    <measurement group_id="B9" value="45.0" spread="11.8"/>
                    <measurement group_id="B10" value="32.5" spread="10.9"/>
                    <measurement group_id="B11" value="39.0" spread="16.6"/>
                    <measurement group_id="B12" value="41.1" spread="14.5"/>
                    <measurement group_id="B13" value="53.1" spread="10.7"/>
                    <measurement group_id="B14" value="40.0" spread="14.4"/>
                    <measurement group_id="B15" value="44.9" spread="15.7"/>
                    <measurement group_id="B16" value="36.1" spread="12.7"/>
                    <measurement group_id="B17" value="31.5" spread="13.1"/>
                    <measurement group_id="B18" value="44.1" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="6"/>
                    <measurement group_id="B15" value="8"/>
                    <measurement group_id="B16" value="6"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="5"/>
                    <measurement group_id="B15" value="8"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="10"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="11"/>
                    <measurement group_id="B13" value="10"/>
                    <measurement group_id="B14" value="9"/>
                    <measurement group_id="B15" value="15"/>
                    <measurement group_id="B16" value="11"/>
                    <measurement group_id="B17" value="4"/>
                    <measurement group_id="B18" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="10"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="9"/>
                    <measurement group_id="B15" value="10"/>
                    <measurement group_id="B16" value="10"/>
                    <measurement group_id="B17" value="3"/>
                    <measurement group_id="B18" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an Adverse Event (AE)</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
        <time_frame>Up to 2 weeks after vaccination on Day 1, Month 1 and Month 6 (up to Day 15, Week 6 and Week 26)</time_frame>
        <population>All randomized participants who received at least 1 vaccination and had follow-up safety data available</population>
        <group_list>
          <group group_id="O1">
            <title>HCMV Seropositive (+) V160 10u Intramuscular (IM)</title>
            <description>Participants seropositive for Human cytomegalovirus (HCMV) at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>HCMV + V160 30u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>HCMV+ V160 100u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>HCMV+ V160 100u MAPA IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 plus Merck Aluminum Phosphate Adjuvant (MAPA) adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O5">
            <title>HCMV+ V160 250u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O6">
            <title>HCMV+ Placebo IM</title>
            <description>Participants seropositive for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O7">
            <title>HCMV+ V160 30u ID</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by intradermal (ID) injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O8">
            <title>HCMV+ Placebo ID</title>
            <description>Participants seropositive for HCMV at Baseline received vaccination with placebo by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O9">
            <title>HCMV Seronegative (-) V160 10u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O10">
            <title>HCMV- V160 30u IM</title>
            <description>Participants seronegative for HCMV at Baseline received vaccination with 30u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O11">
            <title>HCMV- V160 30u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O12">
            <title>HCMV- V160 100u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O13">
            <title>HCMV- V160 100u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O14">
            <title>HCMV- V160 250u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O15">
            <title>HCMV- V160 Placebo IM</title>
            <description>Participants seronegative for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O16">
            <title>HCMV- V160 30u ID</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O17">
            <title>HCMV- Placebo ID</title>
            <description>Participants seronegative for HCMV at Baseline received placebo by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Adverse Event (AE)</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
          <population>All randomized participants who received at least 1 vaccination and had follow-up safety data available</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="10"/>
                <count group_id="O12" value="11"/>
                <count group_id="O13" value="10"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="16"/>
                <count group_id="O16" value="11"/>
                <count group_id="O17" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="92.9"/>
                    <measurement group_id="O3" value="84.6"/>
                    <measurement group_id="O4" value="100.0"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="57.9"/>
                    <measurement group_id="O7" value="100.0"/>
                    <measurement group_id="O8" value="50.0"/>
                    <measurement group_id="O9" value="75.0"/>
                    <measurement group_id="O10" value="90.0"/>
                    <measurement group_id="O11" value="90.0"/>
                    <measurement group_id="O12" value="100.0"/>
                    <measurement group_id="O13" value="90.0"/>
                    <measurement group_id="O14" value="90.9"/>
                    <measurement group_id="O15" value="56.3"/>
                    <measurement group_id="O16" value="100.0"/>
                    <measurement group_id="O17" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an Injection-site AE</title>
        <description>Injection-site AEs are defined as redness, swelling, and pain/tenderness.</description>
        <time_frame>Up to 2 weeks after vaccination on Day 1, Month 1 and Month 6 (up to Day 15, Week 6 and Week 26)</time_frame>
        <population>All randomized participants who received at least 1 vaccination and had follow-up safety data available</population>
        <group_list>
          <group group_id="O1">
            <title>HCMV Seropositive (+) V160 10u Intramuscular (IM)</title>
            <description>Participants seropositive for Human cytomegalovirus (HCMV) at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>HCMV + V160 30u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>HCMV+ V160 100u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>HCMV+ V160 100u MAPA IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 plus Merck Aluminum Phosphate Adjuvant (MAPA) adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O5">
            <title>HCMV+ V160 250u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O6">
            <title>HCMV+ Placebo IM</title>
            <description>Participants seropositive for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O7">
            <title>HCMV+ V160 30u ID</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by intradermal (ID) injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O8">
            <title>HCMV+ Placebo ID</title>
            <description>Participants seropositive for HCMV at Baseline received vaccination with placebo by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O9">
            <title>HCMV Seronegative (-) V160 10u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O10">
            <title>HCMV- V160 30u IM</title>
            <description>Participants seronegative for HCMV at Baseline received vaccination with 30u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O11">
            <title>HCMV- V160 30u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O12">
            <title>HCMV- V160 100u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O13">
            <title>HCMV- V160 100u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O14">
            <title>HCMV- V160 250u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O15">
            <title>HCMV- V160 Placebo IM</title>
            <description>Participants seronegative for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O16">
            <title>HCMV- V160 30u ID</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O17">
            <title>HCMV- Placebo ID</title>
            <description>Participants seronegative for HCMV at Baseline received placebo by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Injection-site AE</title>
          <description>Injection-site AEs are defined as redness, swelling, and pain/tenderness.</description>
          <population>All randomized participants who received at least 1 vaccination and had follow-up safety data available</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="10"/>
                <count group_id="O12" value="11"/>
                <count group_id="O13" value="10"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="16"/>
                <count group_id="O16" value="11"/>
                <count group_id="O17" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="69.2"/>
                    <measurement group_id="O4" value="80.0"/>
                    <measurement group_id="O5" value="100.0"/>
                    <measurement group_id="O6" value="26.3"/>
                    <measurement group_id="O7" value="90.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="66.7"/>
                    <measurement group_id="O10" value="80.0"/>
                    <measurement group_id="O11" value="80.0"/>
                    <measurement group_id="O12" value="90.9"/>
                    <measurement group_id="O13" value="90.0"/>
                    <measurement group_id="O14" value="81.8"/>
                    <measurement group_id="O15" value="31.3"/>
                    <measurement group_id="O16" value="100.0"/>
                    <measurement group_id="O17" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Systemic AE</title>
        <description>A Systemic AE includes, but is not exclusive of, the following AEs: fatigue, myalgia, headache and joint pain</description>
        <time_frame>Up to 2 weeks after vaccination on Day 1, Month 1 and Month 6 (up to Day 15, Week 6 and Week 26)</time_frame>
        <population>All randomized participants who received at least 1 vaccination and had follow-up safety data available</population>
        <group_list>
          <group group_id="O1">
            <title>HCMV Seropositive (+) V160 10u Intramuscular (IM)</title>
            <description>Participants seropositive for Human cytomegalovirus (HCMV) at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>HCMV + V160 30u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>HCMV+ V160 100u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>HCMV+ V160 100u MAPA IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 plus Merck Aluminum Phosphate Adjuvant (MAPA) adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O5">
            <title>HCMV+ V160 250u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O6">
            <title>HCMV+ Placebo IM</title>
            <description>Participants seropositive for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O7">
            <title>HCMV+ V160 30u ID</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by intradermal (ID) injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O8">
            <title>HCMV+ Placebo ID</title>
            <description>Participants seropositive for HCMV at Baseline received vaccination with placebo by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O9">
            <title>HCMV Seronegative (-) V160 10u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O10">
            <title>HCMV- V160 30u IM</title>
            <description>Participants seronegative for HCMV at Baseline received vaccination with 30u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O11">
            <title>HCMV- V160 30u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O12">
            <title>HCMV- V160 100u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O13">
            <title>HCMV- V160 100u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O14">
            <title>HCMV- V160 250u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O15">
            <title>HCMV- V160 Placebo IM</title>
            <description>Participants seronegative for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O16">
            <title>HCMV- V160 30u ID</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O17">
            <title>HCMV- Placebo ID</title>
            <description>Participants seronegative for HCMV at Baseline received placebo by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Systemic AE</title>
          <description>A Systemic AE includes, but is not exclusive of, the following AEs: fatigue, myalgia, headache and joint pain</description>
          <population>All randomized participants who received at least 1 vaccination and had follow-up safety data available</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="10"/>
                <count group_id="O12" value="11"/>
                <count group_id="O13" value="10"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="16"/>
                <count group_id="O16" value="11"/>
                <count group_id="O17" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="64.3"/>
                    <measurement group_id="O3" value="69.2"/>
                    <measurement group_id="O4" value="90.0"/>
                    <measurement group_id="O5" value="90.9"/>
                    <measurement group_id="O6" value="57.9"/>
                    <measurement group_id="O7" value="80.0"/>
                    <measurement group_id="O8" value="50.0"/>
                    <measurement group_id="O9" value="66.7"/>
                    <measurement group_id="O10" value="90.0"/>
                    <measurement group_id="O11" value="70.0"/>
                    <measurement group_id="O12" value="100.0"/>
                    <measurement group_id="O13" value="70.0"/>
                    <measurement group_id="O14" value="90.9"/>
                    <measurement group_id="O15" value="56.3"/>
                    <measurement group_id="O16" value="100.0"/>
                    <measurement group_id="O17" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Serious Adverse Event (SAE)</title>
        <description>A serious adverse event is any adverse event occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event</description>
        <time_frame>Up to 2 weeks after vaccination on Day 1, Month 1 and Month 6 (up to Day 15, Week 6 and Week 26)</time_frame>
        <population>All randomized participants who received at least 1 vaccination and had follow-up safety data available</population>
        <group_list>
          <group group_id="O1">
            <title>HCMV Seropositive (+) V160 10u Intramuscular (IM)</title>
            <description>Participants seropositive for Human cytomegalovirus (HCMV) at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>HCMV + V160 30u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>HCMV+ V160 100u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>HCMV+ V160 100u MAPA IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 plus Merck Aluminum Phosphate Adjuvant (MAPA) adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O5">
            <title>HCMV+ V160 250u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O6">
            <title>HCMV+ Placebo IM</title>
            <description>Participants seropositive for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O7">
            <title>HCMV+ V160 30u ID</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by intradermal (ID) injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O8">
            <title>HCMV+ Placebo ID</title>
            <description>Participants seropositive for HCMV at Baseline received vaccination with placebo by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O9">
            <title>HCMV Seronegative (-) V160 10u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O10">
            <title>HCMV- V160 30u IM</title>
            <description>Participants seronegative for HCMV at Baseline received vaccination with 30u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O11">
            <title>HCMV- V160 30u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O12">
            <title>HCMV- V160 100u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O13">
            <title>HCMV- V160 100u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O14">
            <title>HCMV- V160 250u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O15">
            <title>HCMV- V160 Placebo IM</title>
            <description>Participants seronegative for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O16">
            <title>HCMV- V160 30u ID</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O17">
            <title>HCMV- Placebo ID</title>
            <description>Participants seronegative for HCMV at Baseline received placebo by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Serious Adverse Event (SAE)</title>
          <description>A serious adverse event is any adverse event occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event</description>
          <population>All randomized participants who received at least 1 vaccination and had follow-up safety data available</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="10"/>
                <count group_id="O12" value="11"/>
                <count group_id="O13" value="10"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="16"/>
                <count group_id="O16" value="11"/>
                <count group_id="O17" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Serious Vaccine-Related Adverse Event</title>
        <description>A serious adverse event is any adverse event occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. A serious vaccine-related adverse event was determined by the investigator to be related to the vaccine.</description>
        <time_frame>Up to 2 weeks after vaccination on Day 1, Month 1 and Month 6 (up to Day 15, Week 6 and Week 26)</time_frame>
        <population>All randomized participants who received at least 1 vaccination and had follow-up safety data available</population>
        <group_list>
          <group group_id="O1">
            <title>HCMV Seropositive (+) V160 10u Intramuscular (IM)</title>
            <description>Participants seropositive for Human cytomegalovirus (HCMV) at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>HCMV + V160 30u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>HCMV+ V160 100u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>HCMV+ V160 100u MAPA IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 plus Merck Aluminum Phosphate Adjuvant (MAPA) adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O5">
            <title>HCMV+ V160 250u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O6">
            <title>HCMV+ Placebo IM</title>
            <description>Participants seropositive for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O7">
            <title>HCMV+ V160 30u ID</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by intradermal (ID) injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O8">
            <title>HCMV+ Placebo ID</title>
            <description>Participants seropositive for HCMV at Baseline received vaccination with placebo by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O9">
            <title>HCMV Seronegative (-) V160 10u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O10">
            <title>HCMV- V160 30u IM</title>
            <description>Participants seronegative for HCMV at Baseline received vaccination with 30u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O11">
            <title>HCMV- V160 30u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O12">
            <title>HCMV- V160 100u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O13">
            <title>HCMV- V160 100u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O14">
            <title>HCMV- V160 250u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O15">
            <title>HCMV- V160 Placebo IM</title>
            <description>Participants seronegative for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O16">
            <title>HCMV- V160 30u ID</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O17">
            <title>HCMV- Placebo ID</title>
            <description>Participants seronegative for HCMV at Baseline received placebo by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Serious Vaccine-Related Adverse Event</title>
          <description>A serious adverse event is any adverse event occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. A serious vaccine-related adverse event was determined by the investigator to be related to the vaccine.</description>
          <population>All randomized participants who received at least 1 vaccination and had follow-up safety data available</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="10"/>
                <count group_id="O12" value="11"/>
                <count group_id="O13" value="10"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="16"/>
                <count group_id="O16" value="11"/>
                <count group_id="O17" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued Study Treatment Due to an AE</title>
        <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
        <time_frame>Up to Month 6</time_frame>
        <population>All randomized participants who received at least 1 vaccination and had follow-up safety data available</population>
        <group_list>
          <group group_id="O1">
            <title>HCMV Seropositive (+) V160 10u Intramuscular (IM)</title>
            <description>Participants seropositive for Human cytomegalovirus (HCMV) at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>HCMV + V160 30u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>HCMV+ V160 100u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>HCMV+ V160 100u MAPA IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 plus Merck Aluminum Phosphate Adjuvant (MAPA) adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O5">
            <title>HCMV+ V160 250u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O6">
            <title>HCMV+ Placebo IM</title>
            <description>Participants seropositive for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O7">
            <title>HCMV+ V160 30u ID</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by intradermal (ID) injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O8">
            <title>HCMV+ Placebo ID</title>
            <description>Participants seropositive for HCMV at Baseline received vaccination with placebo by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O9">
            <title>HCMV Seronegative (-) V160 10u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O10">
            <title>HCMV- V160 30u IM</title>
            <description>Participants seronegative for HCMV at Baseline received vaccination with 30u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O11">
            <title>HCMV- V160 30u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O12">
            <title>HCMV- V160 100u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O13">
            <title>HCMV- V160 100u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O14">
            <title>HCMV- V160 250u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O15">
            <title>HCMV- V160 Placebo IM</title>
            <description>Participants seronegative for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O16">
            <title>HCMV- V160 30u ID</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O17">
            <title>HCMV- Placebo ID</title>
            <description>Participants seronegative for HCMV at Baseline received placebo by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Study Treatment Due to an AE</title>
          <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol - specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
          <population>All randomized participants who received at least 1 vaccination and had follow-up safety data available</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="10"/>
                <count group_id="O12" value="11"/>
                <count group_id="O13" value="10"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="16"/>
                <count group_id="O16" value="11"/>
                <count group_id="O17" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="9.1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="9.1"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="9.1"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Events of Clinical Interest (ECI)</title>
        <description>An event of clinical interest (ECI) is identified as any overdose, elevated liver values meeting threshold criteria (aspartate aminotransferase or alanine aminotransferase ≥3x upper limit of normal (ULN); total bilirubin ≥2x ULN, and, at the same time, alkaline phosphatase &lt;2xULN). Additionally, confirmed, diagnosed autoimmune conditions are considered ECIs.</description>
        <time_frame>Up to 18 months</time_frame>
        <population>All randomized participants who received at least 1 vaccination and had follow-up safety data available</population>
        <group_list>
          <group group_id="O1">
            <title>HCMV Seropositive (+) V160 10u Intramuscular (IM)</title>
            <description>Participants seropositive for Human cytomegalovirus (HCMV) at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>HCMV + V160 30u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>HCMV+ V160 100u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>HCMV+ V160 100u MAPA IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 plus Merck Aluminum Phosphate Adjuvant (MAPA) adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O5">
            <title>HCMV+ V160 250u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O6">
            <title>HCMV+ Placebo IM</title>
            <description>Participants seropositive for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O7">
            <title>HCMV+ V160 30u ID</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by intradermal (ID) injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O8">
            <title>HCMV+ Placebo ID</title>
            <description>Participants seropositive for HCMV at Baseline received vaccination with placebo by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O9">
            <title>HCMV Seronegative (-) V160 10u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O10">
            <title>HCMV- V160 30u IM</title>
            <description>Participants seronegative for HCMV at Baseline received vaccination with 30u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O11">
            <title>HCMV- V160 30u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O12">
            <title>HCMV- V160 100u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O13">
            <title>HCMV- V160 100u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O14">
            <title>HCMV- V160 250u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O15">
            <title>HCMV- V160 Placebo IM</title>
            <description>Participants seronegative for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O16">
            <title>HCMV- V160 30u ID</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O17">
            <title>HCMV- Placebo ID</title>
            <description>Participants seronegative for HCMV at Baseline received placebo by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Events of Clinical Interest (ECI)</title>
          <description>An event of clinical interest (ECI) is identified as any overdose, elevated liver values meeting threshold criteria (aspartate aminotransferase or alanine aminotransferase ≥3x upper limit of normal (ULN); total bilirubin ≥2x ULN, and, at the same time, alkaline phosphatase &lt;2xULN). Additionally, confirmed, diagnosed autoimmune conditions are considered ECIs.</description>
          <population>All randomized participants who received at least 1 vaccination and had follow-up safety data available</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="10"/>
                <count group_id="O12" value="11"/>
                <count group_id="O13" value="10"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="16"/>
                <count group_id="O16" value="11"/>
                <count group_id="O17" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer of HCMV-specific Neutralizing Antibody After Vaccination 3</title>
        <description>Serum samples for measuring neutralizing antibodies using the Merck Neutralizing Antibody (NAb) assay were collected at month 7. The LiCor-based near-infrared dye (NIRDye) In-Cell Western (ICW) HCMV microneutralization assay was used to detect and quantify anti-HCMV neutralizing antibodies. The primary hypothesis was that for HCMV-seronegative participants, at least 1 of the vaccination groups receiving V160 formulated with or without adjuvant would exhibit higher HCMV-specific neutralizing antibody titers than the placebo group.</description>
        <time_frame>Month 7 (1 month after vaccination 3 at Month 6)</time_frame>
        <population>All randomized participants who received at least 1 dose of the study vaccine or placebo and had at least 1 valid neutralizing antibody result.</population>
        <group_list>
          <group group_id="O1">
            <title>HCMV Seropositive (+) V160 10u Intramuscular (IM)</title>
            <description>Participants seropositive for Human cytomegalovirus (HCMV) at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>HCMV + V160 30u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>HCMV+ V160 100u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>HCMV+ V160 100u MAPA IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 plus Merck Aluminum Phosphate Adjuvant (MAPA) adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O5">
            <title>HCMV+ V160 250u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O6">
            <title>HCMV+ V160 30u ID</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by intradermal (ID) injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O7">
            <title>HCMV+ Placebo IM or ID</title>
            <description>Participants seropositive for HCMV at Baseline received vaccination with placebo by IM or ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O8">
            <title>HCMV Seronegative (-) V160 10u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O9">
            <title>HCMV- V160 30u IM</title>
            <description>Participants seronegative for HCMV at Baseline received vaccination with 30u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O10">
            <title>HCMV- V160 30u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O11">
            <title>HCMV- V160 100u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O12">
            <title>HCMV- V160 100u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O13">
            <title>HCMV- V160 250u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O14">
            <title>HCMV- V160 30u ID</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O15">
            <title>HCMV- Placebo IM or ID</title>
            <description>Participants seronegative for HCMV at Baseline received placebo by IM or ID injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of HCMV-specific Neutralizing Antibody After Vaccination 3</title>
          <description>Serum samples for measuring neutralizing antibodies using the Merck Neutralizing Antibody (NAb) assay were collected at month 7. The LiCor-based near-infrared dye (NIRDye) In-Cell Western (ICW) HCMV microneutralization assay was used to detect and quantify anti-HCMV neutralizing antibodies. The primary hypothesis was that for HCMV-seronegative participants, at least 1 of the vaccination groups receiving V160 formulated with or without adjuvant would exhibit higher HCMV-specific neutralizing antibody titers than the placebo group.</description>
          <population>All randomized participants who received at least 1 dose of the study vaccine or placebo and had at least 1 valid neutralizing antibody result.</population>
          <units>Geometric Mean Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="19"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="10"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="9"/>
                <count group_id="O12" value="9"/>
                <count group_id="O13" value="10"/>
                <count group_id="O14" value="11"/>
                <count group_id="O15" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3301" lower_limit="2097" upper_limit="5197"/>
                    <measurement group_id="O2" value="4177" lower_limit="2721" upper_limit="6412"/>
                    <measurement group_id="O3" value="7740" lower_limit="4190" upper_limit="14297"/>
                    <measurement group_id="O4" value="5701" lower_limit="3526" upper_limit="9218"/>
                    <measurement group_id="O5" value="3535" lower_limit="2115" upper_limit="5907"/>
                    <measurement group_id="O6" value="8601" lower_limit="5305" upper_limit="13944"/>
                    <measurement group_id="O7" value="2224" lower_limit="1522" upper_limit="3249"/>
                    <measurement group_id="O8" value="328" lower_limit="210" upper_limit="511"/>
                    <measurement group_id="O9" value="1532" lower_limit="1075" upper_limit="2182"/>
                    <measurement group_id="O10" value="1361" lower_limit="886" upper_limit="2090"/>
                    <measurement group_id="O11" value="820" lower_limit="524" upper_limit="1285"/>
                    <measurement group_id="O12" value="2573" lower_limit="1863" upper_limit="3553"/>
                    <measurement group_id="O13" value="1241" lower_limit="699" upper_limit="2203"/>
                    <measurement group_id="O14" value="1261" lower_limit="733" upper_limit="2169"/>
                    <measurement group_id="O15" value="20" lower_limit="20" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>GMT Ratio: GMT V160/GMT placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>GMT Ratio: GMT V160/GMT placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>GMT Ratio: GMT V160/GMT placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.6</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>GMT Ratio: GMT V160/GMT placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>GMT Ratio: GMT V160/GMT placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>GMT Ratio: GMT V160/GMT placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio</param_type>
            <param_value>3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.2</ci_lower_limit>
            <ci_upper_limit>7.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>GMT Ratio: GMT V160/GMT placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Hypothesis is GMT Ratio &gt;1</p_value_desc>
            <method>Two sample t-test</method>
            <param_type>GMT Ratio</param_type>
            <param_value>16.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.5</ci_lower_limit>
            <ci_upper_limit>28.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>GMT Ratio: GMT V160/GMT placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Hypothesis is GMT Ratio &gt;1</p_value_desc>
            <method>Two sample t-test</method>
            <param_type>GMT Ratio</param_type>
            <param_value>76.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49.5</ci_lower_limit>
            <ci_upper_limit>118.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>GMT Ratio: GMT V160/GMT placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Hypothesis is GMT Ratio &gt;1</p_value_desc>
            <method>Two sample t-test</method>
            <param_type>GMT Ratio</param_type>
            <param_value>68.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>40.1</ci_lower_limit>
            <ci_upper_limit>115.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>GMT Ratio: GMT V160/GMT placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Hypothesis is GMT Ratio &gt;1</p_value_desc>
            <method>Two sample t-test</method>
            <param_type>GMT Ratio</param_type>
            <param_value>41.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.8</ci_lower_limit>
            <ci_upper_limit>70.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>GMT Ratio: GMT V160/GMT placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Hypothesis is GMT Ratio &gt;1</p_value_desc>
            <method>Two sample t-test</method>
            <param_type>GMT Ratio</param_type>
            <param_value>128.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.0</ci_lower_limit>
            <ci_upper_limit>190.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O13</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>GMT Ratio: GMT V160/GMT placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Hypothesis is GMT Ratio &gt;1</p_value_desc>
            <method>Two sample t-test</method>
            <param_type>GMT Ratio</param_type>
            <param_value>62.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>30.5</ci_lower_limit>
            <ci_upper_limit>126.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O14</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>GMT Ratio: GMT V160/GMT placebo</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Hypothesis is GMT Ratio &gt;1</p_value_desc>
            <method>Two sample t-test</method>
            <param_type>GMT Ratio</param_type>
            <param_value>63.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.9</ci_lower_limit>
            <ci_upper_limit>124.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Count of Peripheral Blood Mononuclear Cells Secreting Interferon-Gamma</title>
        <description>In order to evaluate the cellular immune response to the vaccine(s), the HCMV enzyme-linked immunospot (ELISPOT) assay was used to detect interferon gamma (IFN-γ) secreting HCMV-specific cells from peripheral blood mononuclear cells (PBMCs). Results are expressed as the frequency of spot forming cells (SFCs) per million PBMCs (SFC/10^6 PBMCs). Results are presented for the following HCMV proteins: pp65, Immediate early Protein 1 (IE1), Immediate early Protein 2 (IE2), Glycoprotein B (gB), and also for purified HCMV virion stock.</description>
        <time_frame>Month 7 (1 month after vaccination 3 at Month 6)</time_frame>
        <population>All randomized participants who received at least 1 dose of the study vaccine or placebo and had at least 1 valid PBMC interferon-gamma result.</population>
        <group_list>
          <group group_id="O1">
            <title>HCMV Seropositive (+) V160 10u Intramuscular (IM)</title>
            <description>Participants seropositive for Human cytomegalovirus (HCMV) at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>HCMV + V160 30u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>HCMV+ V160 100u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>HCMV+ V160 100u MAPA IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 plus Merck Aluminum Phosphate Adjuvant (MAPA) adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O5">
            <title>HCMV+ V160 250u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O6">
            <title>HCMV+ V160 30u ID</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by intradermal (ID) injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O7">
            <title>HCMV+ Placebo IM or ID</title>
            <description>Participants seropositive for HCMV at Baseline received vaccination with placebo by IM or ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O8">
            <title>HCMV Seronegative (-) V160 10u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O9">
            <title>HCMV- V160 30u IM</title>
            <description>Participants seronegative for HCMV at Baseline received vaccination with 30u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O10">
            <title>HCMV- V160 30u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O11">
            <title>HCMV- V160 100u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O12">
            <title>HCMV- V160 100u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O13">
            <title>HCMV- V160 250u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O14">
            <title>HCMV- V160 30u ID</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O15">
            <title>HCMV- Placebo IM or ID</title>
            <description>Participants seronegative for HCMV at Baseline received placebo by IM or ID injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Count of Peripheral Blood Mononuclear Cells Secreting Interferon-Gamma</title>
          <description>In order to evaluate the cellular immune response to the vaccine(s), the HCMV enzyme-linked immunospot (ELISPOT) assay was used to detect interferon gamma (IFN-γ) secreting HCMV-specific cells from peripheral blood mononuclear cells (PBMCs). Results are expressed as the frequency of spot forming cells (SFCs) per million PBMCs (SFC/10^6 PBMCs). Results are presented for the following HCMV proteins: pp65, Immediate early Protein 1 (IE1), Immediate early Protein 2 (IE2), Glycoprotein B (gB), and also for purified HCMV virion stock.</description>
          <population>All randomized participants who received at least 1 dose of the study vaccine or placebo and had at least 1 valid PBMC interferon-gamma result.</population>
          <units>SFC/10^6 PBMCs</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="8"/>
                <count group_id="O13" value="10"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pp65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="7"/>
                    <count group_id="O10" value="10"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="10"/>
                    <count group_id="O14" value="7"/>
                    <count group_id="O15" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="819" lower_limit="362" upper_limit="1853"/>
                    <measurement group_id="O2" value="419" lower_limit="174" upper_limit="1007"/>
                    <measurement group_id="O3" value="1384" lower_limit="66" upper_limit="2873"/>
                    <measurement group_id="O4" value="1105" lower_limit="422" upper_limit="2892"/>
                    <measurement group_id="O5" value="1206" lower_limit="565" upper_limit="2573"/>
                    <measurement group_id="O6" value="1080" lower_limit="570" upper_limit="2047"/>
                    <measurement group_id="O7" value="800" lower_limit="457" upper_limit="1401"/>
                    <measurement group_id="O8" value="886" lower_limit="394" upper_limit="1993"/>
                    <measurement group_id="O9" value="468" lower_limit="195" upper_limit="1125"/>
                    <measurement group_id="O10" value="865" lower_limit="429" upper_limit="1745"/>
                    <measurement group_id="O11" value="380" lower_limit="144" upper_limit="999"/>
                    <measurement group_id="O12" value="1325" lower_limit="656" upper_limit="2679"/>
                    <measurement group_id="O13" value="512" lower_limit="174" upper_limit="1502"/>
                    <measurement group_id="O14" value="1145" lower_limit="530" upper_limit="2474"/>
                    <measurement group_id="O15" value="19" lower_limit="11" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IE1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="7"/>
                    <count group_id="O10" value="10"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="10"/>
                    <count group_id="O14" value="7"/>
                    <count group_id="O15" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="855" lower_limit="262" upper_limit="2786"/>
                    <measurement group_id="O2" value="340" lower_limit="85" upper_limit="1353"/>
                    <measurement group_id="O3" value="419" lower_limit="106" upper_limit="1660"/>
                    <measurement group_id="O4" value="370" lower_limit="79" upper_limit="1719"/>
                    <measurement group_id="O5" value="417" lower_limit="116" upper_limit="1507"/>
                    <measurement group_id="O6" value="379" lower_limit="111" upper_limit="1299"/>
                    <measurement group_id="O7" value="200" lower_limit="75" upper_limit="533"/>
                    <measurement group_id="O8" value="776" lower_limit="310" upper_limit="1943"/>
                    <measurement group_id="O9" value="358" lower_limit="123" upper_limit="1043"/>
                    <measurement group_id="O10" value="913" lower_limit="416" upper_limit="2003"/>
                    <measurement group_id="O11" value="577" lower_limit="158" upper_limit="2099"/>
                    <measurement group_id="O12" value="933" lower_limit="384" upper_limit="2264"/>
                    <measurement group_id="O13" value="742" lower_limit="326" upper_limit="1688"/>
                    <measurement group_id="O14" value="1796" lower_limit="702" upper_limit="4590"/>
                    <measurement group_id="O15" value="12" lower_limit="6" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IE2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="7"/>
                    <count group_id="O10" value="10"/>
                    <count group_id="O11" value="5"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="9"/>
                    <count group_id="O14" value="7"/>
                    <count group_id="O15" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" lower_limit="48" upper_limit="312"/>
                    <measurement group_id="O2" value="101" lower_limit="47" upper_limit="216"/>
                    <measurement group_id="O3" value="309" lower_limit="151" upper_limit="631"/>
                    <measurement group_id="O4" value="72" lower_limit="34" upper_limit="156"/>
                    <measurement group_id="O5" value="93" lower_limit="32" upper_limit="271"/>
                    <measurement group_id="O6" value="32" lower_limit="18" upper_limit="55"/>
                    <measurement group_id="O7" value="49" lower_limit="32" upper_limit="74"/>
                    <measurement group_id="O8" value="119" lower_limit="45" upper_limit="313"/>
                    <measurement group_id="O9" value="22" lower_limit="8" upper_limit="62"/>
                    <measurement group_id="O10" value="34" lower_limit="15" upper_limit="80"/>
                    <measurement group_id="O11" value="146" lower_limit="35" upper_limit="609"/>
                    <measurement group_id="O12" value="86" lower_limit="32" upper_limit="228"/>
                    <measurement group_id="O13" value="131" lower_limit="52" upper_limit="330"/>
                    <measurement group_id="O14" value="194" lower_limit="66" upper_limit="576"/>
                    <measurement group_id="O15" value="10" lower_limit="4" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gB</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="7"/>
                    <count group_id="O10" value="10"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="9"/>
                    <count group_id="O14" value="7"/>
                    <count group_id="O15" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195" lower_limit="69" upper_limit="555"/>
                    <measurement group_id="O2" value="287" lower_limit="74" upper_limit="1117"/>
                    <measurement group_id="O3" value="1137" lower_limit="422" upper_limit="3063"/>
                    <measurement group_id="O4" value="217" lower_limit="58" upper_limit="806"/>
                    <measurement group_id="O5" value="253" lower_limit="84" upper_limit="761"/>
                    <measurement group_id="O6" value="294" lower_limit="101" upper_limit="852"/>
                    <measurement group_id="O7" value="140" lower_limit="64" upper_limit="306"/>
                    <measurement group_id="O8" value="105" lower_limit="58" upper_limit="190"/>
                    <measurement group_id="O9" value="14" lower_limit="6" upper_limit="32"/>
                    <measurement group_id="O10" value="38" lower_limit="22" upper_limit="66"/>
                    <measurement group_id="O11" value="185" lower_limit="73" upper_limit="469"/>
                    <measurement group_id="O12" value="86" lower_limit="45" upper_limit="165"/>
                    <measurement group_id="O13" value="135" lower_limit="73" upper_limit="249"/>
                    <measurement group_id="O14" value="174" lower_limit="89" upper_limit="339"/>
                    <measurement group_id="O15" value="18" lower_limit="11" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Virus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="7"/>
                    <count group_id="O10" value="10"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="10"/>
                    <count group_id="O14" value="7"/>
                    <count group_id="O15" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1190" lower_limit="544" upper_limit="2605"/>
                    <measurement group_id="O2" value="384" lower_limit="114" upper_limit="1294"/>
                    <measurement group_id="O3" value="2134" lower_limit="995" upper_limit="4578"/>
                    <measurement group_id="O4" value="1348" lower_limit="481" upper_limit="3772"/>
                    <measurement group_id="O5" value="1708" lower_limit="732" upper_limit="3988"/>
                    <measurement group_id="O6" value="937" lower_limit="430" upper_limit="2044"/>
                    <measurement group_id="O7" value="1357" lower_limit="714" upper_limit="2579"/>
                    <measurement group_id="O8" value="668" lower_limit="334" upper_limit="1334"/>
                    <measurement group_id="O9" value="79" lower_limit="28" upper_limit="224"/>
                    <measurement group_id="O10" value="268" lower_limit="135" upper_limit="534"/>
                    <measurement group_id="O11" value="621" lower_limit="276" upper_limit="1400"/>
                    <measurement group_id="O12" value="777" lower_limit="420" upper_limit="1439"/>
                    <measurement group_id="O13" value="413" lower_limit="150" upper_limit="1139"/>
                    <measurement group_id="O14" value="1160" lower_limit="597" upper_limit="2253"/>
                    <measurement group_id="O15" value="17" lower_limit="10" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration of Interferon-Gamma After Stimulation of Whole Blood Sample With Pooled HCMV Antigen Peptides</title>
        <description>In response to HCMV-specific stimulation of whole blood specimens the whole Blood Cytokine Stimulation (WBStim) assay was used to detect the secretion of interferon gamma (IFN -γ) by an ELISA assay. Results are presented for the following HCMV proteins: pp65, IE1, and gB.</description>
        <time_frame>Month 7 (1 month after vaccination 3 at Month 6)</time_frame>
        <population>All randomized participants who received at least 1 dose of the study vaccine or placebo and had at least 1 valid whole blood interferon-gamma result.</population>
        <group_list>
          <group group_id="O1">
            <title>HCMV Seropositive (+) V160 10u Intramuscular (IM)</title>
            <description>Participants seropositive for Human cytomegalovirus (HCMV) at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>HCMV + V160 30u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>HCMV+ V160 100u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>HCMV+ V160 100u MAPA IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 plus Merck Aluminum Phosphate Adjuvant (MAPA) adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O5">
            <title>HCMV+ V160 250u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O6">
            <title>HCMV+ V160 30u ID</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by intradermal (ID) injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O7">
            <title>HCMV+ Placebo IM or ID</title>
            <description>Participants seropositive for HCMV at Baseline received vaccination with placebo by IM or ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O8">
            <title>HCMV Seronegative (-) V160 10u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O9">
            <title>HCMV- V160 30u IM</title>
            <description>Participants seronegative for HCMV at Baseline received vaccination with 30u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O10">
            <title>HCMV- V160 30u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O11">
            <title>HCMV- V160 100u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O12">
            <title>HCMV- V160 100u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O13">
            <title>HCMV- V160 250u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O14">
            <title>HCMV- V160 30u ID</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O15">
            <title>HCMV- Placebo IM or ID</title>
            <description>Participants seronegative for HCMV at Baseline received placebo by IM or ID injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration of Interferon-Gamma After Stimulation of Whole Blood Sample With Pooled HCMV Antigen Peptides</title>
          <description>In response to HCMV-specific stimulation of whole blood specimens the whole Blood Cytokine Stimulation (WBStim) assay was used to detect the secretion of interferon gamma (IFN -γ) by an ELISA assay. Results are presented for the following HCMV proteins: pp65, IE1, and gB.</description>
          <population>All randomized participants who received at least 1 dose of the study vaccine or placebo and had at least 1 valid whole blood interferon-gamma result.</population>
          <units>ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="15"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="9"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="7"/>
                <count group_id="O14" value="7"/>
                <count group_id="O15" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pp65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="14"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="8"/>
                    <count group_id="O10" value="8"/>
                    <count group_id="O11" value="9"/>
                    <count group_id="O12" value="6"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="7"/>
                    <count group_id="O15" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" lower_limit="63" upper_limit="445"/>
                    <measurement group_id="O2" value="193" lower_limit="65" upper_limit="571"/>
                    <measurement group_id="O3" value="79" lower_limit="26" upper_limit="242"/>
                    <measurement group_id="O4" value="86" lower_limit="35" upper_limit="209"/>
                    <measurement group_id="O5" value="211" lower_limit="90" upper_limit="492"/>
                    <measurement group_id="O6" value="64" lower_limit="30" upper_limit="136"/>
                    <measurement group_id="O7" value="112" lower_limit="60" upper_limit="210"/>
                    <measurement group_id="O8" value="64" lower_limit="33" upper_limit="122"/>
                    <measurement group_id="O9" value="97" lower_limit="53" upper_limit="176"/>
                    <measurement group_id="O10" value="24" lower_limit="11" upper_limit="56"/>
                    <measurement group_id="O11" value="89" lower_limit="51" upper_limit="156"/>
                    <measurement group_id="O12" value="8" lower_limit="5" upper_limit="14"/>
                    <measurement group_id="O13" value="28" lower_limit="14" upper_limit="56"/>
                    <measurement group_id="O14" value="24" lower_limit="14" upper_limit="39"/>
                    <measurement group_id="O15" value="5" lower_limit="3" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IE1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="15"/>
                    <count group_id="O8" value="8"/>
                    <count group_id="O9" value="8"/>
                    <count group_id="O10" value="9"/>
                    <count group_id="O11" value="9"/>
                    <count group_id="O12" value="6"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="7"/>
                    <count group_id="O15" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="21" upper_limit="389"/>
                    <measurement group_id="O2" value="70" lower_limit="14" upper_limit="364"/>
                    <measurement group_id="O3" value="13" lower_limit="2" upper_limit="74"/>
                    <measurement group_id="O4" value="35" lower_limit="6" upper_limit="217"/>
                    <measurement group_id="O5" value="20" lower_limit="4" upper_limit="109"/>
                    <measurement group_id="O6" value="27" lower_limit="7" upper_limit="104"/>
                    <measurement group_id="O7" value="24" lower_limit="7" upper_limit="82"/>
                    <measurement group_id="O8" value="62" lower_limit="26" upper_limit="148"/>
                    <measurement group_id="O9" value="35" lower_limit="20" upper_limit="62"/>
                    <measurement group_id="O10" value="28" lower_limit="14" upper_limit="55"/>
                    <measurement group_id="O11" value="40" lower_limit="17" upper_limit="96"/>
                    <measurement group_id="O12" value="11" lower_limit="5" upper_limit="23"/>
                    <measurement group_id="O13" value="45" lower_limit="20" upper_limit="101"/>
                    <measurement group_id="O14" value="40" lower_limit="22" upper_limit="72"/>
                    <measurement group_id="O15" value="5" lower_limit="3" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gB</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="15"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="7"/>
                    <count group_id="O10" value="9"/>
                    <count group_id="O11" value="9"/>
                    <count group_id="O12" value="5"/>
                    <count group_id="O13" value="7"/>
                    <count group_id="O14" value="5"/>
                    <count group_id="O15" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="16" upper_limit="175"/>
                    <measurement group_id="O2" value="40" lower_limit="8" upper_limit="202"/>
                    <measurement group_id="O3" value="64" lower_limit="11" upper_limit="375"/>
                    <measurement group_id="O4" value="27" lower_limit="3" upper_limit="213"/>
                    <measurement group_id="O5" value="27" lower_limit="6" upper_limit="115"/>
                    <measurement group_id="O6" value="62" lower_limit="18" upper_limit="214"/>
                    <measurement group_id="O7" value="16" lower_limit="6" upper_limit="48"/>
                    <measurement group_id="O8" value="7" lower_limit="4" upper_limit="11"/>
                    <measurement group_id="O9" value="10" lower_limit="6" upper_limit="19"/>
                    <measurement group_id="O10" value="5" lower_limit="3" upper_limit="9"/>
                    <measurement group_id="O11" value="7" lower_limit="4" upper_limit="12"/>
                    <measurement group_id="O12" value="10" lower_limit="6" upper_limit="16"/>
                    <measurement group_id="O13" value="9" lower_limit="6" upper_limit="16"/>
                    <measurement group_id="O14" value="5" lower_limit="3" upper_limit="9"/>
                    <measurement group_id="O15" value="6" lower_limit="4" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of HCMV-specific Neutralizing Antibody After Vaccinations 1 and 2</title>
        <description>Serum samples for measuring neutralizing antibodies using the Merck NAb assay were collected at months 1 and 2. The LiCor-based near-infrared dye (NIRDye) In-Cell Western (ICW) HCMV microneutralization assay was used to detect and quantify anti-HCMV neutralizing antibodies. Values below the lower limit of titer are represented by NA.</description>
        <time_frame>Month 1 and 2 (one month after vaccination 1 [Day 1] and vaccination 2 [Month 1])</time_frame>
        <population>All randomized participants who received at least 1 dose of the study vaccine or placebo and had at least 1 valid neutralizing antibody result.</population>
        <group_list>
          <group group_id="O1">
            <title>HCMV Seropositive (+) V160 10u Intramuscular (IM)</title>
            <description>Participants seropositive for Human cytomegalovirus (HCMV) at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>HCMV + V160 30u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O3">
            <title>HCMV+ V160 100u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O4">
            <title>HCMV+ V160 100u MAPA IM</title>
            <description>Participants seropositive for HCMV at Baseline received 100u V160 plus Merck Aluminum Phosphate Adjuvant (MAPA) adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O5">
            <title>HCMV+ V160 250u IM</title>
            <description>Participants seropositive for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O6">
            <title>HCMV+ V160 30u ID</title>
            <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by intradermal (ID) injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O7">
            <title>HCMV+ Placebo IM or ID</title>
            <description>Participants seropositive for HCMV at Baseline received vaccination with placebo by IM or ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O8">
            <title>HCMV Seronegative (-) V160 10u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O9">
            <title>HCMV- V160 30u IM</title>
            <description>Participants seronegative for HCMV at Baseline received vaccination with 30u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O10">
            <title>HCMV- V160 30u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O11">
            <title>HCMV- V160 100u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O12">
            <title>HCMV- V160 100u MAPA IM</title>
            <description>Participants seronegative for HCMV at Baseline received 100u V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O13">
            <title>HCMV- V160 250u IM</title>
            <description>Participants seronegative for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O14">
            <title>HCMV- V160 30u ID</title>
            <description>Participants seronegative for HCMV at Baseline received 30u V160 by ID injection on Day 1, Month 1, and Month 6</description>
          </group>
          <group group_id="O15">
            <title>HCMV- Placebo IM or ID</title>
            <description>Participants seronegative for HCMV at Baseline received placebo by IM or ID injection on Day 1, Month 1, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of HCMV-specific Neutralizing Antibody After Vaccinations 1 and 2</title>
          <description>Serum samples for measuring neutralizing antibodies using the Merck NAb assay were collected at months 1 and 2. The LiCor-based near-infrared dye (NIRDye) In-Cell Western (ICW) HCMV microneutralization assay was used to detect and quantify anti-HCMV neutralizing antibodies. Values below the lower limit of titer are represented by NA.</description>
          <population>All randomized participants who received at least 1 dose of the study vaccine or placebo and had at least 1 valid neutralizing antibody result.</population>
          <units>Geometric Mean Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="10"/>
                <count group_id="O10" value="10"/>
                <count group_id="O11" value="11"/>
                <count group_id="O12" value="10"/>
                <count group_id="O13" value="10"/>
                <count group_id="O14" value="10"/>
                <count group_id="O15" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="10"/>
                    <count group_id="O10" value="10"/>
                    <count group_id="O11" value="11"/>
                    <count group_id="O12" value="10"/>
                    <count group_id="O13" value="10"/>
                    <count group_id="O14" value="10"/>
                    <count group_id="O15" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3124" lower_limit="1887" upper_limit="5172"/>
                    <measurement group_id="O2" value="5186" lower_limit="3252" upper_limit="8270"/>
                    <measurement group_id="O3" value="6232" lower_limit="3764" upper_limit="10318"/>
                    <measurement group_id="O4" value="6695" lower_limit="3854" upper_limit="11631"/>
                    <measurement group_id="O5" value="3831" lower_limit="2140" upper_limit="6858"/>
                    <measurement group_id="O6" value="9127" lower_limit="5253" upper_limit="15855"/>
                    <measurement group_id="O7" value="2335" lower_limit="1485" upper_limit="3671"/>
                    <measurement group_id="O8" value="73" lower_limit="NA" upper_limit="137">Values below the lower limit of titer are represented by NA.</measurement>
                    <measurement group_id="O9" value="95" lower_limit="50" upper_limit="184"/>
                    <measurement group_id="O10" value="65" lower_limit="NA" upper_limit="125">Values below the lower limit of titer are represented by NA.</measurement>
                    <measurement group_id="O11" value="91" lower_limit="49" upper_limit="170"/>
                    <measurement group_id="O12" value="134" lower_limit="70" upper_limit="258"/>
                    <measurement group_id="O13" value="281" lower_limit="146" upper_limit="542"/>
                    <measurement group_id="O14" value="183" lower_limit="95" upper_limit="351"/>
                    <measurement group_id="O15" value="NA" lower_limit="NA" upper_limit="NA">Values below the lower limit of titer are represented by NA.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="10"/>
                    <count group_id="O10" value="10"/>
                    <count group_id="O11" value="11"/>
                    <count group_id="O12" value="10"/>
                    <count group_id="O13" value="10"/>
                    <count group_id="O14" value="10"/>
                    <count group_id="O15" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3144" lower_limit="1893" upper_limit="5221"/>
                    <measurement group_id="O2" value="5443" lower_limit="3472" upper_limit="8533"/>
                    <measurement group_id="O3" value="6959" lower_limit="4088" upper_limit="11845"/>
                    <measurement group_id="O4" value="7022" lower_limit="4126" upper_limit="11953"/>
                    <measurement group_id="O5" value="4261" lower_limit="2432" upper_limit="7464"/>
                    <measurement group_id="O6" value="9412" lower_limit="5529" upper_limit="16021"/>
                    <measurement group_id="O7" value="2313" lower_limit="1468" upper_limit="3644"/>
                    <measurement group_id="O8" value="143" lower_limit="89" upper_limit="230"/>
                    <measurement group_id="O9" value="264" lower_limit="160" upper_limit="433"/>
                    <measurement group_id="O10" value="264" lower_limit="161" upper_limit="433"/>
                    <measurement group_id="O11" value="288" lower_limit="180" upper_limit="463"/>
                    <measurement group_id="O12" value="590" lower_limit="359" upper_limit="968"/>
                    <measurement group_id="O13" value="589" lower_limit="359" upper_limit="968"/>
                    <measurement group_id="O14" value="451" lower_limit="275" upper_limit="741"/>
                    <measurement group_id="O15" value="NA" lower_limit="NA" upper_limit="NA">Values below the lower limit of titer are represented by NA.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 18 months</time_frame>
      <desc>All randomized participants who received at least 1 vaccination</desc>
      <group_list>
        <group group_id="E1">
          <title>HCMV + V160 10u IM</title>
          <description>Participants seropositive for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E2">
          <title>HCMV + V160 30u IM</title>
          <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E3">
          <title>HCMV + V160 100u IM</title>
          <description>Participants seropositive for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E4">
          <title>HCMV+ V160 100u MAPA IM</title>
          <description>Participants seropositive for HCMV at Baseline received 100u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E5">
          <title>HCMV + V160 250u IM</title>
          <description>Participants seropositive for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E6">
          <title>HCMV+ Placebo IM</title>
          <description>Participants seropositive for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E7">
          <title>HCMV + V160 30u ID</title>
          <description>Participants seropositive for HCMV at Baseline received 30u V160 vaccination by ID injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E8">
          <title>HCMV+ Placebo ID</title>
          <description>Participants seropositive for HCMV at Baseline received placebo vaccination by ID injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E9">
          <title>HCMV- V160 10u IM</title>
          <description>Participants seronegative for HCMV at Baseline received 10u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E10">
          <title>HCMV- V160 30u IM</title>
          <description>Participants seronegative for HCMV at Baseline received 30u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E11">
          <title>HCMV- V160 30u MAPA IM</title>
          <description>Participants seronegative for HCMV at Baseline received 30u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E12">
          <title>HCMV- V160 100u IM</title>
          <description>Participants seronegative for HCMV at Baseline received 100u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E13">
          <title>HCMV- V160 100u MAPA IM</title>
          <description>Participants seronegative for HCMV at Baseline received 100u V160 plus MAPA adjuvant vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E14">
          <title>HCMV- V160 250u IM</title>
          <description>Participants seronegative for HCMV at Baseline received 250u V160 vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E15">
          <title>HCMV- V160 Placebo IM</title>
          <description>Participants seronegative for HCMV at Baseline received placebo vaccination by IM injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E16">
          <title>HCMV- V160 30u ID</title>
          <description>Participants seronegative for HCMV at Baseline received 30u V160 vaccination by ID injection on Day 1, Month 1, and Month 6</description>
        </group>
        <group group_id="E17">
          <title>HCMV- V160 Placebo ID</title>
          <description>Participants seronegative for HCMV at Baseline received placebo vaccination by ID injection on Day 1, Month 1, and Month 6</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E11" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E14" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E15" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E16" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="6" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E3" events="19" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E4" events="22" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E5" events="19" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E6" events="15" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E7" events="22" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="15" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E10" events="9" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E11" events="13" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E12" events="20" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E13" events="18" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E14" events="37" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E15" events="16" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E16" events="27" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E17" events="3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site discolouration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E7" events="26" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E10" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E12" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E14" events="6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="32" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site joint pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site movement impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" events="31" subjects_affected="12" subjects_at_risk="14"/>
                <counts group_id="E3" events="18" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E4" events="21" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E5" events="35" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E6" events="10" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E7" events="16" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="13" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E10" events="28" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E11" events="19" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E12" events="24" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E13" events="28" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E14" events="35" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E15" events="11" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E16" events="23" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="14" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="18" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site scab</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="27" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="5" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E10" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="4" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E12" events="5" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E13" events="9" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E14" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E16" events="34" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site vesicles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site pustule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Eosinophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Monocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Monocyte count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E4" events="11" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" events="10" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="7" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E11" events="8" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E12" events="5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E13" events="7" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E14" events="8" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E15" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E16" events="14" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E4" events="13" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E5" events="14" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E7" events="10" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="9" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E10" events="12" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E11" events="10" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E12" events="18" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E13" events="12" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E14" events="20" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E15" events="5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E16" events="13" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" events="14" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E4" events="20" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E6" events="13" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E7" events="21" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="10" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E10" events="18" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E11" events="13" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E12" events="17" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E13" events="15" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E14" events="20" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E15" events="8" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E16" events="27" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E15" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

